//Newsletter October 2016

Newsletter October 2016


NEWSWORTHY
AOBiome Announces First-of-its Kind Trial of Live Topical Bacterial Treatment For Acne
 

AOBiome, which has developed and sold, under the Mother Dirt brand, a topical consumer product spray containing ammonia-oxidizing bacteria for maintaining a healthy skin microbiome, has announced its ground-breaking first-in-kind Phase 2B trial of a topical live microbial therapeutic for the treatment of acne.

Come see AOBiome's Chief Medical Officer, Dr. Larry Weiss, speak at our Amgen Innovator Series event on October 11, 2016, details below.

GRADUATES
Alector
 

Alector, one of QB3@953's first companies, is moving on to more spacious locations to continue its development of novel immuno-modulating therapeutics for neurodegenerative diseases. After successfully raising over $60M in 2015 alone and developing multiple clinical candidates, Alector will continue its work in two locations south of our fair city. 

Nucleo Life Sciences
 

Nucleo Life Sciences will be expanding their team to broaden the number of formulation and drug development projects they are tackling.  Borne out of Actera, another former QB3@953 company, Nucleo Life Sciences incubated with us for a little over one year before outgrowing our location. 

 

Congratulations to Alector and Nucleo Life Sciences on your amazing growth and progress!

NEWCOMERS
Enable Biosciences

Enable Biosciences is developing 1000x more sensitive antibody tests for the early detection and treatment of diseases like HIV and type 1 diabetes. Their technology was invented at UC Berkeley and Stanford by Jason Tsai and Peter Robinson in the lab of Carolyn Bertozzi in 2015. Joined by Dr. David Seftel, MD/MBA, Enable's cofounders have participated in UCSF's Lean Launchpad and Startup 101 programs in addition to Stanford's StartX accelerator program. They are the recipients of grants from the NIH, NSF, and Stanford to develop their technology and won the 2016 Harvard Business School New Ventures Competition for Northern California.
UPCOMING EVENTS
October 11, 2016
12 PM - 1 PM
RSVP


Clinical and Cosmetic Development of Ammonia Oxidizing Bacteria

Larry Weiss, MD
Chief Medical Officer, AOBiome

AOBiome LLC is a skin microbiome company focused on the treatment of inflammatory skin conditions and related systemic clinical targets. They are developing a new class of transformational products based on the topical application of beneficial ammonia-oxidizing bacteria (AOB). AOB are naturally occurring chemoautotrophic bacteria that metabolizes the ammonia found in sweat, creating both nitrite and nitric oxide, two critical building blocks of good health.
 
Larry Weiss MD is the Chief Medical Officer at AOBiome.   He has an extensive background in natural products chemistry, microbiology, clinical medicine, and pharmaceutical development and product commercialization. Dr. Weiss is board certified in Anesthesiology, has an MD from Stanford University Medical School, and a BS from Cornell University in Biochemistry. He has a number of patents and is published in the areas of chemistry, electrophysiology, and microbiology.  Dr. Weiss is the founder of CleanWell Company and a Co-Founder of AOBiome.


Sponsored by:

October 26, 2016
12 PM - 1 PM
RSVP


Understanding the How's and Why's of Cell Culture Contamination and Ways to Avoid the Problem

Mark Rothenberg, PhD
Manager Scientific Training and Education, Corning

 
Studies have shown that at least 20% of the animal cultures in existence today are contaminated. Cell line contamination can result in decreased productivity, loss of critical study tools, impact data quality and reduce bioprocessing capacity.

In hopes of helping to reduce this common problem, this seminar will focus on:
  • Understanding the nature of contamination and its consequences
  • Understanding the major sources and causes of cell culture contamination
  • Discussing aseptic technique and its use in reducing day-to-day contamination
  • Simple methods to monitor for

Sponsored by:
November 15, 2016
3 PM - 4 PM
RSVP


Towards Affordable Diagnosis Based on Human Gut Microbiome: Colorectal Cancer as A Case Study

Manimozhiyan Arumugam, PhD
Group Leader and Associate Professor
Novo Nordisk Foundation Center for Basic Metabolic Research
University of Copenhagen, Denmark


Dr. Arumugam leads a research group that investigates how our health and diseases are influenced by our genetics, by the environment we live in, and by our gut microbiome. His research is thus interdisciplinary, combining metagenomics (a technique to study the gut microbiome), (epi)genomics, (epi)genetics, (meta)transcriptomics, and metabolomics. The group also has international collaborations studying the interaction between the gut microbiome and the host in the context of several other diseases, including cardiometabolic diseases, chronic liver diseases and cancer. His group is actively investigating the role of gut microbiome in multiple sclerosis, obesity, alcoholic liver fibrosis and ageing. He has recently started a new research direction to discover novel antibiotics from the human microbiota.
November 16, 2016
3:30 PM - 5:30 PM

More Information


Job Fair for Postdocs and Graduate Students

Career development programs from UC Berkeley, UC San Francisco, and Lawrence Berkeley National Lab will be visiting QB3@953 bringing talent to our companies.  These programs give postdocs an opportunity to learn more about working in industry and helps establish connections at local biotech and pharmaceutical companies.

HELPING ENTREPRENEURS HELP THEMSELVES


Our mission is to help entrepreneurs create successful life science companies, by providing high-quality space and facilities in the setting of a vibrant, self-starting community.
 

Enabling Awesome - One Bench at a Time

2019-01-14T13:37:08+00:00October 1st, 2016|Newsletters 2016|